bIosimilar of aDalimumab, an European evAluation

Inclusion Criteria

• •1. Age ≥18 years, male or female.
• •2. Patients diagnosed with one chronic inflammatory rheumatological (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis) or chronic inflammatory bowel (Crohn's disease, ulcerative colitis) diseases.
• •3. Patients who have been switched to FK adalimumab from the reference product (Humira®) or another adalimumab biosimilar.
• •4. Patients who have been prescribed FK adalimumab according to the SmPC prior to the inclusion.
• •5. Patients able to understand and complete the study questionnaires in local language during the study visits.
• •6. Patients willing to sign informed consent to meet data protection requirements